第57届美国神经精神药理学会年会:美国国家药物滥用研究所公布了TRV734的数据

2018-12-14 MedSci MedSci原创

Trevena是一家生物制药公司,专注于为疼痛患者开发创新治疗方案,近日宣布其TRV734的最新数据已在第57届美国神经精神药理学会年会上发表。

Trevena是一家生物制药公司,专注于为疼痛患者开发创新治疗方案,近日宣布其TRV734的最新数据已在第57届美国神经精神药理学会年会上发表。美国国家药物滥用研究所(NIDA)的行为神经科学研究分部负责人Yavin Shaham博士报告称,该研究对比了Trevena的两种候选化合物TRV130TRV734的数据,结果显示,TRV734显著减少了大鼠复发模型中寻求药物的行为。这些数据表明,TRV734可能成为一种新型的口服维持治疗药物,用于治疗阿片类药物或海洛因成瘾。

Trevena高级副总裁兼首席医疗官Mark A. Demitrack博士说:对于阿片类药物滥用患者,目前的治疗方法,如美沙酮和丁丙诺啡,对某些患者的疗效有限或无效,并且与实质安全性和耐受性有关。我们对迄今为止产生的数据感到鼓舞,并很高兴继续与NIDA合作,进一步调查TRV734对这一未被满足医疗需求的潜在用途


原始出处:

http://www.firstwordpharma.com/node/1611524#axzz5Zd9WQBU4

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1801059, encodeId=70f9180105910, content=<a href='/topic/show?id=79cfe339533' target=_blank style='color:#2F92EE;'>#研究所#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73395, encryptionId=79cfe339533, topicName=研究所)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f63175, createdName=nian.wang1982, createdTime=Thu Oct 31 05:01:00 CST 2019, time=2019-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1801865, encodeId=d1481801865cd, content=<a href='/topic/show?id=53f1e4449fe' target=_blank style='color:#2F92EE;'>#神经精神药理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74449, encryptionId=53f1e4449fe, topicName=神经精神药理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8143398, createdName=lily1616, createdTime=Thu Oct 24 10:01:00 CST 2019, time=2019-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1701572, encodeId=d72c1e01572d2, content=<a href='/topic/show?id=bedc665998e' target=_blank style='color:#2F92EE;'>#滥用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66599, encryptionId=bedc665998e, topicName=滥用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ea1030383785, createdName=zchen, createdTime=Mon Dec 24 22:01:00 CST 2018, time=2018-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1804254, encodeId=f7531804254fd, content=<a href='/topic/show?id=faa8e6578d4' target=_blank style='color:#2F92EE;'>#精神药理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76578, encryptionId=faa8e6578d4, topicName=精神药理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Sat Sep 14 03:01:00 CST 2019, time=2019-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443240, encodeId=80d9144324021, content=<a href='/topic/show?id=51748e807c7' target=_blank style='color:#2F92EE;'>#药物滥用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87807, encryptionId=51748e807c7, topicName=药物滥用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5c1a5038471, createdName=ms6323715314570549, createdTime=Sun Dec 16 05:01:00 CST 2018, time=2018-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1516179, encodeId=e7f815161e9d9, content=<a href='/topic/show?id=7e868e9126b' target=_blank style='color:#2F92EE;'>#药理学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87912, encryptionId=7e868e9126b, topicName=药理学)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=300b10929379, createdName=ms7019579240139182, createdTime=Sun Dec 16 05:01:00 CST 2018, time=2018-12-16, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1801059, encodeId=70f9180105910, content=<a href='/topic/show?id=79cfe339533' target=_blank style='color:#2F92EE;'>#研究所#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73395, encryptionId=79cfe339533, topicName=研究所)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f63175, createdName=nian.wang1982, createdTime=Thu Oct 31 05:01:00 CST 2019, time=2019-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1801865, encodeId=d1481801865cd, content=<a href='/topic/show?id=53f1e4449fe' target=_blank style='color:#2F92EE;'>#神经精神药理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74449, encryptionId=53f1e4449fe, topicName=神经精神药理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8143398, createdName=lily1616, createdTime=Thu Oct 24 10:01:00 CST 2019, time=2019-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1701572, encodeId=d72c1e01572d2, content=<a href='/topic/show?id=bedc665998e' target=_blank style='color:#2F92EE;'>#滥用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66599, encryptionId=bedc665998e, topicName=滥用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ea1030383785, createdName=zchen, createdTime=Mon Dec 24 22:01:00 CST 2018, time=2018-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1804254, encodeId=f7531804254fd, content=<a href='/topic/show?id=faa8e6578d4' target=_blank style='color:#2F92EE;'>#精神药理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76578, encryptionId=faa8e6578d4, topicName=精神药理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Sat Sep 14 03:01:00 CST 2019, time=2019-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443240, encodeId=80d9144324021, content=<a href='/topic/show?id=51748e807c7' target=_blank style='color:#2F92EE;'>#药物滥用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87807, encryptionId=51748e807c7, topicName=药物滥用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5c1a5038471, createdName=ms6323715314570549, createdTime=Sun Dec 16 05:01:00 CST 2018, time=2018-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1516179, encodeId=e7f815161e9d9, content=<a href='/topic/show?id=7e868e9126b' target=_blank style='color:#2F92EE;'>#药理学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87912, encryptionId=7e868e9126b, topicName=药理学)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=300b10929379, createdName=ms7019579240139182, createdTime=Sun Dec 16 05:01:00 CST 2018, time=2018-12-16, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1801059, encodeId=70f9180105910, content=<a href='/topic/show?id=79cfe339533' target=_blank style='color:#2F92EE;'>#研究所#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73395, encryptionId=79cfe339533, topicName=研究所)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f63175, createdName=nian.wang1982, createdTime=Thu Oct 31 05:01:00 CST 2019, time=2019-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1801865, encodeId=d1481801865cd, content=<a href='/topic/show?id=53f1e4449fe' target=_blank style='color:#2F92EE;'>#神经精神药理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74449, encryptionId=53f1e4449fe, topicName=神经精神药理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8143398, createdName=lily1616, createdTime=Thu Oct 24 10:01:00 CST 2019, time=2019-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1701572, encodeId=d72c1e01572d2, content=<a href='/topic/show?id=bedc665998e' target=_blank style='color:#2F92EE;'>#滥用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66599, encryptionId=bedc665998e, topicName=滥用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ea1030383785, createdName=zchen, createdTime=Mon Dec 24 22:01:00 CST 2018, time=2018-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1804254, encodeId=f7531804254fd, content=<a href='/topic/show?id=faa8e6578d4' target=_blank style='color:#2F92EE;'>#精神药理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76578, encryptionId=faa8e6578d4, topicName=精神药理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Sat Sep 14 03:01:00 CST 2019, time=2019-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443240, encodeId=80d9144324021, content=<a href='/topic/show?id=51748e807c7' target=_blank style='color:#2F92EE;'>#药物滥用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87807, encryptionId=51748e807c7, topicName=药物滥用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5c1a5038471, createdName=ms6323715314570549, createdTime=Sun Dec 16 05:01:00 CST 2018, time=2018-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1516179, encodeId=e7f815161e9d9, content=<a href='/topic/show?id=7e868e9126b' target=_blank style='color:#2F92EE;'>#药理学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87912, encryptionId=7e868e9126b, topicName=药理学)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=300b10929379, createdName=ms7019579240139182, createdTime=Sun Dec 16 05:01:00 CST 2018, time=2018-12-16, status=1, ipAttribution=)]
    2018-12-24 zchen
  4. [GetPortalCommentsPageByObjectIdResponse(id=1801059, encodeId=70f9180105910, content=<a href='/topic/show?id=79cfe339533' target=_blank style='color:#2F92EE;'>#研究所#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73395, encryptionId=79cfe339533, topicName=研究所)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f63175, createdName=nian.wang1982, createdTime=Thu Oct 31 05:01:00 CST 2019, time=2019-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1801865, encodeId=d1481801865cd, content=<a href='/topic/show?id=53f1e4449fe' target=_blank style='color:#2F92EE;'>#神经精神药理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74449, encryptionId=53f1e4449fe, topicName=神经精神药理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8143398, createdName=lily1616, createdTime=Thu Oct 24 10:01:00 CST 2019, time=2019-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1701572, encodeId=d72c1e01572d2, content=<a href='/topic/show?id=bedc665998e' target=_blank style='color:#2F92EE;'>#滥用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66599, encryptionId=bedc665998e, topicName=滥用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ea1030383785, createdName=zchen, createdTime=Mon Dec 24 22:01:00 CST 2018, time=2018-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1804254, encodeId=f7531804254fd, content=<a href='/topic/show?id=faa8e6578d4' target=_blank style='color:#2F92EE;'>#精神药理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76578, encryptionId=faa8e6578d4, topicName=精神药理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Sat Sep 14 03:01:00 CST 2019, time=2019-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443240, encodeId=80d9144324021, content=<a href='/topic/show?id=51748e807c7' target=_blank style='color:#2F92EE;'>#药物滥用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87807, encryptionId=51748e807c7, topicName=药物滥用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5c1a5038471, createdName=ms6323715314570549, createdTime=Sun Dec 16 05:01:00 CST 2018, time=2018-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1516179, encodeId=e7f815161e9d9, content=<a href='/topic/show?id=7e868e9126b' target=_blank style='color:#2F92EE;'>#药理学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87912, encryptionId=7e868e9126b, topicName=药理学)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=300b10929379, createdName=ms7019579240139182, createdTime=Sun Dec 16 05:01:00 CST 2018, time=2018-12-16, status=1, ipAttribution=)]
    2019-09-14 zutt
  5. [GetPortalCommentsPageByObjectIdResponse(id=1801059, encodeId=70f9180105910, content=<a href='/topic/show?id=79cfe339533' target=_blank style='color:#2F92EE;'>#研究所#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73395, encryptionId=79cfe339533, topicName=研究所)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f63175, createdName=nian.wang1982, createdTime=Thu Oct 31 05:01:00 CST 2019, time=2019-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1801865, encodeId=d1481801865cd, content=<a href='/topic/show?id=53f1e4449fe' target=_blank style='color:#2F92EE;'>#神经精神药理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74449, encryptionId=53f1e4449fe, topicName=神经精神药理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8143398, createdName=lily1616, createdTime=Thu Oct 24 10:01:00 CST 2019, time=2019-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1701572, encodeId=d72c1e01572d2, content=<a href='/topic/show?id=bedc665998e' target=_blank style='color:#2F92EE;'>#滥用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66599, encryptionId=bedc665998e, topicName=滥用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ea1030383785, createdName=zchen, createdTime=Mon Dec 24 22:01:00 CST 2018, time=2018-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1804254, encodeId=f7531804254fd, content=<a href='/topic/show?id=faa8e6578d4' target=_blank style='color:#2F92EE;'>#精神药理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76578, encryptionId=faa8e6578d4, topicName=精神药理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Sat Sep 14 03:01:00 CST 2019, time=2019-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443240, encodeId=80d9144324021, content=<a href='/topic/show?id=51748e807c7' target=_blank style='color:#2F92EE;'>#药物滥用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87807, encryptionId=51748e807c7, topicName=药物滥用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5c1a5038471, createdName=ms6323715314570549, createdTime=Sun Dec 16 05:01:00 CST 2018, time=2018-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1516179, encodeId=e7f815161e9d9, content=<a href='/topic/show?id=7e868e9126b' target=_blank style='color:#2F92EE;'>#药理学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87912, encryptionId=7e868e9126b, topicName=药理学)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=300b10929379, createdName=ms7019579240139182, createdTime=Sun Dec 16 05:01:00 CST 2018, time=2018-12-16, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1801059, encodeId=70f9180105910, content=<a href='/topic/show?id=79cfe339533' target=_blank style='color:#2F92EE;'>#研究所#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73395, encryptionId=79cfe339533, topicName=研究所)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f63175, createdName=nian.wang1982, createdTime=Thu Oct 31 05:01:00 CST 2019, time=2019-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1801865, encodeId=d1481801865cd, content=<a href='/topic/show?id=53f1e4449fe' target=_blank style='color:#2F92EE;'>#神经精神药理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74449, encryptionId=53f1e4449fe, topicName=神经精神药理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8143398, createdName=lily1616, createdTime=Thu Oct 24 10:01:00 CST 2019, time=2019-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1701572, encodeId=d72c1e01572d2, content=<a href='/topic/show?id=bedc665998e' target=_blank style='color:#2F92EE;'>#滥用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66599, encryptionId=bedc665998e, topicName=滥用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ea1030383785, createdName=zchen, createdTime=Mon Dec 24 22:01:00 CST 2018, time=2018-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1804254, encodeId=f7531804254fd, content=<a href='/topic/show?id=faa8e6578d4' target=_blank style='color:#2F92EE;'>#精神药理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76578, encryptionId=faa8e6578d4, topicName=精神药理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Sat Sep 14 03:01:00 CST 2019, time=2019-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443240, encodeId=80d9144324021, content=<a href='/topic/show?id=51748e807c7' target=_blank style='color:#2F92EE;'>#药物滥用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87807, encryptionId=51748e807c7, topicName=药物滥用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5c1a5038471, createdName=ms6323715314570549, createdTime=Sun Dec 16 05:01:00 CST 2018, time=2018-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1516179, encodeId=e7f815161e9d9, content=<a href='/topic/show?id=7e868e9126b' target=_blank style='color:#2F92EE;'>#药理学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87912, encryptionId=7e868e9126b, topicName=药理学)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=300b10929379, createdName=ms7019579240139182, createdTime=Sun Dec 16 05:01:00 CST 2018, time=2018-12-16, status=1, ipAttribution=)]

相关资讯

国家药物滥用监测报告:丧尸药滥用约增3倍,98%来自山西

8月11日,国家食品药品监督管理总局发布《国家药物滥用监测年度报告(2016年)》。年度报告对2016年我国药物滥用监测情况进行了分析,重点描述了海洛因、合成毒品、医疗用药品以及新发生药物滥用情况,并通过比较近五年的监测数据,显示了我国药物滥用现状、特征以及流行趋势。记者注意到,该报告还公布了甲卡西酮等的滥用数量的滥用情况。药物滥用监测数据表明,2016年甲卡西酮滥用数量(707例)达到201

Am J Manag Care:研究揭示处方药监测方案的弊端!

过去几十年,处方药过量造成的死亡人数增加了七倍以上,公共卫生官员称这一流行病是美国历史上最严重的毒品危机。

Natur子刊:中国农业大学院士研究组警示抗生素滥用问题

来自中国农业大学的沈建忠教授研究团队对中国的养殖场、屠宰场和超市进行了抽样调查,发现在中国家禽生产流程中普遍存在能让细菌对碳青霉烯和粘菌素产生耐药性的基因。

苯二氮䓬类药物临床使用专家共识

自1960年世界上第一个苯二氮䓬类药物(BZDs)氯氮䓬(利眠宁)上市以来,BZDs的临床使用已有半个多世纪。时至今日,尽管已有某些与BZDs治疗效应相似的药物,如非苯二氮䓬类催眠药,新一代的抗抑郁、抗焦虑药物等。但BZDs以其起效快、疗效肯定、相对安全等优势而仍广泛应用于临床各科,且具有不可替代的地位。然而,调研却发现,尚有不少同行对BZDs的药理特性、药物选择、使用方法、合理使用的理念、滥用与

FDA批准应用程序治疗物质使用障碍

FDA已批准用于治疗物质使用障碍(SUDs)的移动应用程序——reSET,该程序提供认知行为治疗,以帮助患者避免药物滥用。

BMJ:美国不同种族中年人群死亡率变化趋势

研究发现,美国各种族人群中年死亡率呈现出上升的趋势,几乎全部种族人群的药物滥用死亡率均大幅上升